pharmaceutical
Lilly moves quickly to secure $1.6bn buyout of Armo
May 10, 2018Medical Communications, Sales and Marketing Armo Biosciences, Eli Lilly, biotech, drugs, pharma, pharmaceutical
Armo BioSciences only went public in January but it has already been snapped up by Eli Lilly for $1.6 billion. …
Lodo and Roche go digging for drug candidates, after $1bn deal
May 10, 2018Sales and Marketing Genentech, Roche, biotech, drugs, pharma, pharmaceutical
Discovering potential therapeutics from natural sources has been a constant throughout the evolution of medicine, Lodo Therapeutics, however, has taken …
Novartis’ $1.2m payment to Trump’s lawyer raises more questions than answers
May 10, 2018Medical Communications Essential Consultants, Michael Cohen, Novartis, President trump, Trump, biotech, drugs, pharma, pharmaceutical
Novartis payment to President Trump’s personal lawyer, Michael Cohen, had seemed fairly odd from the beginning – with many asking …
GSK’s CFO chooses to exit company
May 9, 2018Medical Communications GSK, biotech, drugs, pharma, pharmaceutical
Simon Dingemans has been Chief Financial Officer at GSK since 2011 but has now chosen to retire from the position …
Old osteoporosis drug could be used to treat hair loss
May 9, 2018Research and Development biotech, drugs, hair loss, pharma, pharmaceutical
Researchers from the University of Manchester’s Centre for Dermatology Research have made a breakthrough towards the holy grail of the …
Novartis caught in the Stormy Daniels affair, after huge payment to Trump’s lawyer
May 9, 2018Medical Communications, Research and Development Cohen, Novartis, President trump, Trump, biotech, drugs, pharma, pharmaceutical
Novartis has suddenly found itself embroiled in the Stormy Daniels affair, after the lawyer representing her, Michael Avenatti, included the …
Mallinckrodt gets two thumbs down from FDA for jaundice drug
May 4, 2018Medical Communications, Sales and Marketing InfaCare, Mallinckrodt, biotech, drugs, pharma, pharmaceutical
Mallinckrodt paid $80 million, with a further $345 million dependent on milestones, to acquire InfaCare in the hope that the …
Free webinar – Rational EU risk management for oncology medicines
May 4, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing NDA Group, biotech, drugs, pharma, pharmaceutical
It is timely to reflect on how we can best implement the revised GVP module (V) concerning risk management in …
BMS looks to leverage real-world data, with Flatiron collab
May 3, 2018Medical Communications, Sales and Marketing Bristol-Myers Squibb, Flatiron health, biotech, drugs, pharma, pharmaceutical
Bristol-Myers Squibb has extended its existing collaboration with Flatiron Health by three years and expanded the efforts both will be …
Speakers Announced for Veeva R&D Summit, Europe
May 3, 2018Medical Communications biotech, drugs, pharma, pharmaceutical, veeva
In the pharma industry, we tend to use a lot of acronyms. Even in every day life, we are shortening …
Sandoz US woes continue with biosimilar rejection
May 3, 2018Sales and Marketing Novartis, Sandoz, biosimilars, biotech, drugs, pharma, pharmaceutical
In Novartis’ recently released Q1 results, which largely beat analysts’ estimates, Sandoz was a black spot on its record – …
450,000 missed breast cancer screenings, 270 lives potentially shortened
May 2, 2018Medical Communications Jeremy Hunt, NHS, UK, biotech, drugs, pharma, pharmaceutical
An error in the automated system left 450,000 women without an invite for breast screening and Jeremy Hunt, the UK’s …
Samsung BioLogics’ shares down $6bn after accounting furore
May 2, 2018Research and Development, Sales and Marketing Samsung BioLogics, Samsung Bioepis, biotech, drugs, pharma, pharmaceutical, south korea
Samsung BioLogics’ shares have been hit hard, after the South Korean company was handed a notice of suspected breach of …
Novartis becomes first to gain second CAR T indication
May 2, 2018Research and Development, Sales and Marketing Gilead, Kymriah, Novartis, Yescarta, biotech, drugs, pharma, pharmaceutical
Novartis has announced that its CAR T treatment, Kymriah, has successfully been given a second indication for the treatment of …
Sanofi/Regeneron forced to slash price in wake of slow sales
May 1, 2018Research and Development, Sales and Marketing Regeneron, Sanofi, biotech, drugs, pharma, pharmaceutical, praluent
Sanofi and Regeneron were touted as having a sure-fire blockbuster on their hands when they first brought Praluent to market …
Latest content
Santen joins inaugural Global Summit for Eye Health as partner
